• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

用于解释造血移植后不同骨髓完整性患者重组人红细胞生成素(rhEpo)药代动力学变化的全靶介导药物处置(TMDD)模型。

A Full Target-Mediated Drug Disposition (TMDD) Model to Explain the Changes in Recombinant Human Erythropoietin (rhEpo) Pharmacokinetics in Patients with Different Bone Marrow Integrity Following Hematopoietic Transplantation.

机构信息

Division of Pharmaceutics and Translational Therapeutics, College of Pharmacy, University of Iowa, Iowa city, Iowa, USA.

Department of Pediatrics, Roy J. and Lucille A. Carver College of Medicine, University of Iowa, Iowa City, Iowa, USA.

出版信息

J Pharm Sci. 2022 Sep;111(9):2620-2629. doi: 10.1016/j.xphs.2022.06.003. Epub 2022 Jun 9.

DOI:10.1016/j.xphs.2022.06.003
PMID:35691608
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC9391296/
Abstract

Our aim was to build a mechanistic full target-mediated drug disposition (TMDD) model for rhEpo to better understand rhEpo disposition, Epo receptor (EpoR) synthesis, and degradation in hematopoietic transplant patients with four distinct bone marrow conditions. All PK data were analyzed simultaneously using the nonlinear mixed effect modeling approach with NONMEM. The final model was a two-compartmental full TMDD model, which adequately characterizes rhEpo PK in patients and provides insight into the dynamics of free EpoR, rhEpo-EpoR, and total EpoR. The model predicted association rate constant (k), dissociation rate constant (k), and internalization rate constant (k) were 0.0276 pMh, 0.647 h, and 0.255h, respectively, which were supported by experimental data. Also, the EpoR degradation rate constant (k) was estimated to be 0.461 h. EpoR production rate was estimated to be 37.5 pM/h for adults at pre-ablation baseline and 5.91 pM/h, and 4.19 pM/h in the early post-transplant post-engraftment, and late post-transplant full engraftment. Our model provides extensive information on the dynamics of free EpoR, total EpoR and rhEpo-EpoR, and proven to be more robust and can provide more physiologically relevant binding parameters than previous models.

摘要

我们的目的是建立一个针对 rhEpo 的机制性全靶介导药物处置(TMDD)模型,以更好地了解 rhEpo 在接受四种不同骨髓状况的造血移植患者中的处置、Epo 受体(EpoR)合成和降解情况。所有 PK 数据均使用 NONMEM 进行非线性混合效应建模方法进行了同步分析。最终模型是一个两室全 TMDD 模型,它充分描述了患者中 rhEpo 的 PK,并深入了解了游离 EpoR、rhEpo-EpoR 和总 EpoR 的动力学。该模型预测的结合速率常数(k)、解离速率常数(k)和内化速率常数(k)分别为 0.0276 pMh、0.647 h 和 0.255 h,这些参数得到了实验数据的支持。此外,还估计了 EpoR 降解速率常数(k)为 0.461 h。在消融前基线时,成人的 EpoR 生成率估计为 37.5 pM/h,在移植后的早期、晚期和完全植入后,分别为 5.91 pM/h 和 4.19 pM/h。我们的模型提供了关于游离 EpoR、总 EpoR 和 rhEpo-EpoR 动力学的广泛信息,并且被证明比以前的模型更稳健,可以提供更具生理学相关性的结合参数。

相似文献

1
A Full Target-Mediated Drug Disposition (TMDD) Model to Explain the Changes in Recombinant Human Erythropoietin (rhEpo) Pharmacokinetics in Patients with Different Bone Marrow Integrity Following Hematopoietic Transplantation.用于解释造血移植后不同骨髓完整性患者重组人红细胞生成素(rhEpo)药代动力学变化的全靶介导药物处置(TMDD)模型。
J Pharm Sci. 2022 Sep;111(9):2620-2629. doi: 10.1016/j.xphs.2022.06.003. Epub 2022 Jun 9.
2
Pharmacokinetics and pharmacodynamics of erythropoietin receptor in healthy volunteers.健康志愿者中促红细胞生成素受体的药代动力学和药效学
Naunyn Schmiedebergs Arch Pharmacol. 2008 Jun;377(4-6):637-45. doi: 10.1007/s00210-007-0225-z. Epub 2007 Dec 11.
3
Pharmacokinetic analysis of continuous erythropoietin receptor activator disposition in adult sheep using a target-mediated, physiologic recirculation model and a tracer interaction methodology.采用基于靶标的生理再循环模型和示踪剂相互作用方法分析成年绵羊中持续红细胞生成素受体激活剂的药代动力学。
Drug Metab Dispos. 2011 Apr;39(4):603-9. doi: 10.1124/dmd.110.036236. Epub 2011 Jan 5.
4
Skin regeneration with conical and hair follicle structure of deep second-degree scalding injuries via combined expression of the EPO receptor and beta common receptor by local subcutaneous injection of nanosized rhEPO.通过局部皮下注射纳米 rhEPO 联合表达 EPO 受体和β共同受体促进深二度烫伤创面的圆锥形和毛囊结构皮肤再生。
Int J Nanomedicine. 2012;7:1227-37. doi: 10.2147/IJN.S28186. Epub 2012 Mar 6.
5
The enigma of the metabolic fate of circulating erythropoietin (Epo) in view of the pharmacokinetics of the recombinant drugs rhEpo and NESP.鉴于重组药物重组人促红细胞生成素(rhEpo)和新型促红细胞生成素(NESP)的药代动力学,循环促红细胞生成素(Epo)的代谢命运之谜。
Eur J Haematol. 2002 Nov-Dec;69(5-6):265-74. doi: 10.1034/j.1600-0609.2002.02813.x.
6
Differential pharmacokinetic analysis of in vivo erythropoietin receptor interaction with erythropoietin and continuous erythropoietin receptor activator in sheep.绵羊体内促红细胞生成素受体与促红细胞生成素和持续型促红细胞生成素受体激活剂相互作用的药代动力学差异分析。
Biopharm Drug Dispos. 2011 Jul;32(5):276-88. doi: 10.1002/bdd.757. Epub 2011 Jun 15.
7
Erythropoietin (EPO)-receptor signaling induces cell death of primary myeloma cells in vitro.促红细胞生成素(EPO)受体信号传导在体外可诱导原发性骨髓瘤细胞死亡。
J Hematol Oncol. 2016 Aug 31;9(1):75. doi: 10.1186/s13045-016-0306-x.
8
Selection between Michaelis-Menten and target-mediated drug disposition pharmacokinetic models.米氏-门坦与靶控药物处置药代动力学模型的选择。
J Pharmacokinet Pharmacodyn. 2010 Feb;37(1):25-47. doi: 10.1007/s10928-009-9142-8. Epub 2009 Dec 10.
9
Targeted near-infrared imaging of the erythropoietin receptor in human lung cancer xenografts.人肺癌异种移植中红细胞生成素受体的靶向近红外成像。
J Nucl Med. 2012 Feb;53(2):304-11. doi: 10.2967/jnumed.111.091124. Epub 2012 Jan 6.
10
Target-mediated pharmacokinetic and pharmacodynamic model of recombinant human erythropoietin (rHuEPO).重组人促红细胞生成素(rHuEPO)的靶点介导药代动力学和药效学模型。
J Pharmacokinet Pharmacodyn. 2007 Dec;34(6):849-68. doi: 10.1007/s10928-007-9074-0. Epub 2007 Oct 18.

本文引用的文献

1
First-in-human clinical trial to assess pharmacokinetics, pharmacodynamics, safety, and tolerability of iscalimab, an anti-CD40 monoclonal antibody.首例人体临床试验评估iscalimab(一种抗 CD40 单克隆抗体)的药代动力学、药效学、安全性和耐受性。
Am J Transplant. 2020 Feb;20(2):463-473. doi: 10.1111/ajt.15661. Epub 2019 Dec 6.
2
Target-mediated disposition population pharmacokinetics model of erythropoietin in premature neonates following multiple intravenous and subcutaneous dosing regimens.早产儿多次静脉和皮下给药后红细胞生成素的基于靶标的处置群体药代动力学模型。
Eur J Pharm Sci. 2019 Oct 1;138:105013. doi: 10.1016/j.ejps.2019.105013. Epub 2019 Jul 21.
3
A Mechanism-Based Population Pharmacokinetics Model of Erythropoietin in Premature Infants and Healthy Adults Following Multiple Intravenous Doses.
基于机制的早产儿和健康成年人多次静脉注射促红细胞生成素的群体药代动力学模型。
J Clin Pharmacol. 2019 Jun;59(6):835-846. doi: 10.1002/jcph.1368. Epub 2019 Jan 7.
4
A quick scoping review of efficacy, safety, economic, and health-related quality-of-life outcomes of short- and long-acting erythropoiesis-stimulating agents in the treatment of chemotherapy-induced anemia and chronic kidney disease anemia.治疗化疗引起的贫血和慢性肾脏病贫血的短效和长效红细胞生成刺激剂的疗效、安全性、经济学和健康相关生活质量结局的快速范围综述。
Crit Rev Oncol Hematol. 2018 Sep;129:79-90. doi: 10.1016/j.critrevonc.2018.06.010. Epub 2018 Jun 19.
5
High-dose erythropoietin population pharmacokinetics in neonates with hypoxic-ischemic encephalopathy receiving hypothermia.接受低温治疗的新生儿缺氧缺血性脑病患者中高剂量促红细胞生成素的群体药代动力学
Pediatr Res. 2017 Jun;81(6):865-872. doi: 10.1038/pr.2017.15. Epub 2017 Jan 18.
6
A model-based approach to predicting the human pharmacokinetics of a monoclonal antibody exhibiting target-mediated drug disposition.基于模型的方法预测表现出靶介导药物处置的单克隆抗体的人体药代动力学。
J Pharmacol Exp Ther. 2012 Jun;341(3):702-8. doi: 10.1124/jpet.112.191999. Epub 2012 Mar 13.
7
Twist and shout: one decade of meta-analyses of erythropoiesis-stimulating agents in cancer patients.扭转乾坤:十年来癌症患者中促红细胞生成刺激剂的荟萃分析。
Acta Haematol. 2011;125(1-2):55-67. doi: 10.1159/000318897. Epub 2010 Dec 8.
8
Evidence of receptor-mediated elimination of erythropoietin by analysis of erythropoietin receptor mRNA expression in bone marrow and erythropoietin clearance during anemia.通过分析骨髓中促红细胞生成素受体 mRNA 表达和贫血期间促红细胞生成素清除率来证明促红细胞生成素的受体介导清除。
J Pharmacol Exp Ther. 2010 May;333(2):528-32. doi: 10.1124/jpet.109.163568. Epub 2010 Jan 26.
9
The application of target information and preclinical pharmacokinetic/pharmacodynamic modeling in predicting clinical doses of a Dickkopf-1 antibody for osteoporosis.目标信息和临床前药代动力学/药效学模型在预测骨质疏松症 Dickkopf-1 抗体临床剂量中的应用。
J Pharmacol Exp Ther. 2010 Apr;333(1):2-13. doi: 10.1124/jpet.109.164129. Epub 2010 Jan 20.
10
Population pharmacokinetic modeling of epoetin delta in pediatric patients with chronic kidney disease.慢性肾病患儿中δ-促红细胞生成素的群体药代动力学建模
J Clin Pharmacol. 2008 Jul;48(7):837-48. doi: 10.1177/0091270008318218. Epub 2008 May 19.